Setterwalls has advised Asgard Therapeutics AB in connection with a EUR 30 million Series A financing

Setterwalls has advised Asgard Therapeutics AB (“Asgard Therapeutics”) in connection with a EUR 30 million financing. The Series A round was co-led led by RV Invest GmbH and Johnson & Johnson Innovation – JJDC, Inc., with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.

Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, raises EUR 30 million in a Series A financing. The funds will be used to support development of Asgard Therapeutics lead program AT-108 to IND-readiness by 2026, expand and reinforce research and development team, and fuel new reprogramming modalities and delivery platforms to strengthen the pipeline.